Irinotecan, Gemcitabine and Radiation Therapy for Pancreatic Cancer
Phase 2
Completed
- Conditions
- Pancreatic Cancer
- Registration Number
- NCT00192712
- Lead Sponsor
- Rambam Health Care Campus
- Brief Summary
The study hypothesis is that chemoradiation based on 2 drugs will improve local control and long-term survival in patients with locally advanced pancreatic cancer. That is why gemcitabine and irinotecan are combined in an induction phase of 2 months and then this IrinoGem combination is given for 3 more cycles, in reduced doses,concurently with irradiation.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 20
Inclusion Criteria
- locally advanced pancreatic cancer
- performance status 0-2
- normal blood count and chemistry
- no previous chemotherapy or radiotherapy
Read More
Exclusion Criteria
- serious concurrent systemic disease
Read More
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method time to treatment failure
- Secondary Outcome Measures
Name Time Method response rate, survival, toxicity
Trial Locations
- Locations (1)
Department of Oncology, Rambam Medical Center
🇮🇱Haifa, Israel